請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/42885完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 于明暉 | |
| dc.contributor.author | Li-Ying Chen | en |
| dc.contributor.author | 陳俐穎 | zh_TW |
| dc.date.accessioned | 2021-06-15T01:27:30Z | - |
| dc.date.available | 2019-07-31 | |
| dc.date.copyright | 2009-09-16 | |
| dc.date.issued | 2009 | |
| dc.date.submitted | 2009-07-22 | |
| dc.identifier.citation | 1. Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma:epidemiological characteristics and disease burden. J Viral Hepat 2009;16(7):453-63.
2. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis2003;23(1):47-58. 3. Merican I, Guan R, Amarapuka D, Alexander MJ, Chutaputti A, Chien RN, et al.Chronic hepatitis B virus infection in Asian countries. Journal of Gastroenterology and Hepatology 2000;15(12):1356-1361. 4. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362(9399):1907-17. 5. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009;49(5 Suppl):S45-55. 6. Parkin. Estimating the world cancer burden: Globocan 2000. International Journal of Cancer 2001;94(2):153. 7. Wu CF, Yu MW, Lin CL, Liu CJ, Shih WL, Tsai KS, et al. Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men. Carcinogenesis 2008;29(1):106-12. 8. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006;118(12):3030-44. 9. Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002;97(1):72-81. 10. Caldwell. The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology Journal of Gastroenterology 2009;44(s19):96. 11. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295(1):65-73. 12. Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis 2005;25(2):212-25. 13. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005;25 Suppl 1:3-8. 14. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115(2):209-18. 15. Li J-T, Liao Z-X, Ping J, Xu D, Wang H. Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies. Journal of Gastroenterology 19 2008;43(6):419-428. 16. Kitamura T, Watanabe S, Sato N. Liver regeneration, liver cancers and cyclins. J Gastroenterol Hepatol 1998;13 Suppl:S96-9. 17. Kuriyama S, Yokoyama F, Inoue H, Takano J, Ogawa M, Kita Y, et al. Sequential assessment of the intrahepatic expression of epidermal growth factor and transforming growth factor-beta1 in hepatofibrogenesis of a rat cirrhosis model. Int J Mol Med 2007;19(2):317-24. 18. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420(6917):860-867. 19. Coleman WB. Mechanisms of human hepatocarcinogenesis. Curr Mol Med 2003;3(6):573-88. 20. Fabregat I, Roncero C, Fernández M. Survival and apoptosis: a dysregulated balance in liver cancer. Liver International 2007;27(2):155-162. 21. Singletary SE, Baker FL, Spitzer G, Tucker SL, Tomasovic B, Brock WA, et al. Biological effect of epidermal growth factor on the in vitro growth of human tumors. Cancer Res 1987;47(2):403-6. 22. Lanuti M, Liu G, Goodwin JM, Zhai R, Fuchs BC, Asomaning K, et al. A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome. Clin Cancer Res 2008;14(10):3216-22. 23. Borlak J. Epidermal growth factor-induced Hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours. Oncogene 2005;24(11):1809. 24. Stoscheck CM, King LE, Jr. Role of epidermal growth factor in carcinogenesis. Cancer Res 1986;46(3):1030-7. 25. Rescan C, Coutant A, Talarmin H, Theret N, Glaise D, Guguen-Guillouzo C, et al. Mechanism in the sequential control of cell morphology and S phase entry by epidermal growth factor involves distinct MEK/ERK activations. Mol Biol Cell 2001;12(3):725-38. 26. Wang Y, Ripperger J, Fey GH, Samols D, Kordula T, Wetzler M, et al. Modulation of hepatic acute phase gene expression by epidermal growth factor and Src protein tyrosine kinases in murine and human hepatic cells. Hepatology 1999;30(3):682-97. 27. Pang RW, Poon RT. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 2007;72 Suppl 1:30-44. 28. Henson ES, Gibson SB. Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: Implications for cancer therapy. Cellular Signalling 2006;18(12):2089-2097. 29. Ostrowski J, Woszczynski M, Kowalczyk P, Trzeciak L, Hennig E, Bomsztyk K. Treatment of mice with EGF and orthovanadate activates cytoplasmic and nuclear MAPK, p70S6k, and p90rsk in the liver. Journal of Hepatology 2000;32(6):965-974. 30. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007;1773(8):1263-84. 31. Klein PJ, Schmidt CM, Wiesenauer CA, Choi JN, Gage EA, Yip-Schneider MT, et al. The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer. Neoplasia 2006;8(1):1-8. 32. Furuse J. Growth factors as therapeutic targets in HCC. Crit Rev Oncol Hematol 2008;67(1):8-15. 33. Johnson DH. Gefitinib (Iressa) trials in non-small cell lung cancer. Lung Cancer 2003;41(Supplement 1):23-28. 34. Ueda S, Basaki Y, Yoshie M, Ogawa K, Sakisaka S, Kuwano M, et al. PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib. Cancer Res 2006;66(10):5346-53. 35. Schiffer EH, C. Cacheux, W. Wendum, D. Desbois-Mouthon, C. Rey, C. Clergue, F. Poupon, R. Barbu, V. Rosmorduc, O. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 2005;41(2):307. 36. Höpfner M, Sutter AP, Huether A, Schuppan D, Zeitz M, Scherübl H. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. Journal of Hepatology 2004;41(6):1008-1016. 37. Barreiros AP, Sprinzl M, Rosset S, Hohler T, Otto G, Theobald M, et al. EGF and HGF levels are increased during active HBV infection and enhance survival signaling through extracellular matrix interactions in primary human hepatocytes. Int J Cancer 2009;124(1):120-9. 38. Spindler K-LG, Nielsen JN, Ornskov D, Brandslund I, Jakobsen A. Epidermal growth factor (EGF) A61G polymorphism and EGF gene expression in normal colon tissue from patients with colorectal cancer. Acta Oncologica 2007;46(8):1113 - 1117. 39. Shih WL, Yu MW, Chen PJ, Yeh SH, Lo MT, Chang HC, et al. Localization of a susceptibility locus for hepatocellular carcinoma to chromosome 4q in a hepatitis B hyperendemic area. Oncogene 2006;25(22):3219-24. 40. Tanabe KK, Lemoine A, Finkelstein DM, Kawasaki H, Fujii T, Chung RT, et al. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA 2008;299(1):53-60. 41. Shahbazi M, Pravica V, Nasreen N, Fakhoury H, Fryer AA, Strange RC, et al. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 2002;359(9304):397-401. 42. Lim YJ, Kim J-W, Song JY, Hong M-S, Jin S-Y, Yoon SH, et al. Epidermal growth factor gene polymorphism is different between schizophrenia and lung cancer patients in Korean population. Neuroscience Letters 2005;374(3):157-160. 43. Vishnoi M, Pandey SN, Modi DR, Kumar A, Mittal B. Genetic susceptibility of epidermal growth factor +61A>G and transforming growth factor [beta]1 -509C>T gene polymorphisms with gallbladder cancer. Human Immunology 2008;69(6):360-367. 44. Yu MW, Yang YC, Yang SY, Cheng SW, Liaw YF, Lin SM, et al. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. J Natl Cancer Inst 2001;93(21):1644-51. 45. Kirschberg O, Schuttler C, Repp R, Schaefer S. A multiplex-PCR to identify hepatitis B virus--enotypes A-F. J Clin Virol 2004;29(1):39-43. 46. Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005;97(4):265-72. 47. C. Berasain, J. Castillo, M.J. Perugorria, M.U. Latasa, J. Prieto, M.A. Avila. Inflammation and Liver Cancer. Annals of the New York Academy of Sciences 2009;1155(Steroid Enzymes and Cancer):206-221. 48. Mankouri J, Griffin S, Harris M. The hepatitis C virus non-structural protein NS5A alters the trafficking profile of the epidermal growth factor receptor. Traffic 2008;9(9):1497-509. 49. Schorr O, Borel C, Trepo C, Zoulim F, Hantz O. Effects of liver growth factors on hepadnavirus replication in chronically infected duck hepatocytes. J Hepatol 2006;44(5):842-7. 50. Brenndorfer ED, Karthe J, Frelin L, Cebula P, Erhardt A, Schulte am Esch J, et al. Nonstructural 3/4A protease of hepatitis C virus activates epithelial growth factor-induced signal transduction by cleavage of the T-cell protein tyrosine phosphatase. Hepatology 2009;49(6):1810-20. 51. Costa BM, Ferreira P, Costa S, Canedo P, Oliveira P, Silva A, et al. Association between functional EGF+61 polymorphism and glioma risk. Clin Cancer Res 2007;13(9):2621-6. 52. Teixeira AL, Ribeiro R, Cardoso D, Pinto D, Lobo F, Fraga A, et al. Genetic Polymorphism in EGF Is Associated with Prostate Cancer Aggressiveness and Progression-Free Interval in Androgen Blockade-Treated Patients. Clin Cancer Res 2008;14(11):3367-3371. 53. Pao W, Miller VA. Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non-Small-Cell Lung Cancer: Current Knowledge and Future Directions. J Clin Oncol 2005;23(11):2556-2568. 54. Mason RA, Morlock EV, Karagas MR, Kelsey KT, Marsit CJ, Schned AR, et al. EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis. Carcinogenesis 2009;30(7):1155-1160. 55. Lupberger J, Hildt E. Hepatitis B virus-induced oncogenesis. World J Gastroenterol 2007;13(1):74-81. 56. Cougot D, Neuveut C, Buendia MA. HBV induced carcinogenesis. Journal of Clinical Virology 2005;34(Supplement 1):S75-S78. 57. Fausto N. Liver regeneration. Journal of Hepatology 2000;32(Supplement 1):19-31. 58. Komuves LG, Feren A, Jones AL, Fodor E. Expression of epidermal growth factor and its receptor in cirrhotic liver disease. J Histochem Cytochem 2000;48(6):821-30. 59. Mullhaupt B, Feren A, Fodor E, Jones A. Liver expression of epidermal growth factor RNA. Rapid increases in immediate-early phase of liver regeneration. J Biol Chem 1994;269(31):19667-70. 60. Hosgood HD, 3rd, Menashe I, Shen M, Yeager M, Yuenger J, Rajaraman P, et al. Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway. Carcinogenesis 2008;29(10):1938-43. 61. Jacobs EJ, Hsing AW, Bain EB, Stevens VL, Wang Y, Chen J, et al. Polymorphisms in Angiogenesis-Related Genes and Prostate Cancer. Cancer Epidemiol Biomarkers Prev 2008;17(4):972-977. 62. Cheung WY, Zhai R, Kulke M, Heist R, Asomaning K, Ma C, et al. Epidermal Growth Factor A61G Gene Polymorphism, Gastroesophageal Reflux Disease, and Esophageal Adenocarcinoma Risk. Carcinogenesis 2009:bgp126. 63. Okamoto I, Roka F, Krogler J, Endler G, Kaufmann S, Tockner S, et al. The EGF A61G Polymorphism Is Associated with Disease-Free Period and Survival in Malignant Melanoma. J Invest Dermatol 2006;126(10):2242-2246. 64. Goto Y, Ando T, Goto H, Hamajima N. No Association Between EGF Gene Polymorphism and Gastric Cancer. Cancer Epidemiol Biomarkers Prev 2005;14(10):2454-2456. 65. Kang S, Kim JW, Park NH, Song YS, Park SY, Kang SB, et al. Epidermal growth factor 61 A/G polymorphism and uterine cervical cancer. Int J Gynecol Cancer 2007;17(2):492-6. 66. Dandri M, Lutgehetmann M, Volz T, Petersen J. Small animal model systems for studying hepatitis B virus replication and pathogenesis. Semin Liver Dis 2006;26(2):181-91. 67. Chandra V, Kar-Roy A, Kumari S, Mayor S, Jameel S. The Hepatitis E Virus ORF3 Protein Modulates Epidermal Growth Factor Receptor Trafficking, STAT3 Translocation, and the Acute-Phase Response. J. Virol. 2008;82(14):7100-7110. 68. Nakano K, Asano R, Tsumoto K, Kwon H, Goins WF, Kumagai I, et al. Herpes simplex virus targeting to the EGF receptor by a gD-specific soluble bridging molecule. Mol Ther 2005;11(4):617-26. 69. Marsh YV, Eppstein DA. Vaccinia virus and the EGF receptor: A portal for infectivity? Journal of Cellular Biochemistry 1987;34(4):239-245. 70. Eppstein DA, Marsh YV, Schreiber AB, Newman SR, Todaro GJ, Nestor JJ. Epidermal growth factor receptor occupancy inhibits vaccinia virus infection. Nature 1985;318(6047):663-665. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/42885 | - |
| dc.description.abstract | 背景：表皮生長因子（EGF）所調控的訊號傳遞影響各種細胞的生長、分化，位在 此基因上的基因多型性可能在上皮細胞癌，例如肝細胞癌的發展佔有重要的地位。方法：本研究選擇了兩個在表皮生長因子基因上的功能性SNP 做分析，分別為5’UTR 上的rs4444903 及exon 15 上的rs11569017。世代研究包括4432 個B 型肝炎帶原男性，分別從公務人員健康檢查及林口長庚紀念醫院在1989 到1992 之間進入，至2007 年約追蹤16 年且已有200 個肝細胞癌病例。本研究也利用長期追蹤病毒量資料、B 型肝炎病毒基因型及B 型肝炎e 抗原狀態等病毒因子來評估B型肝炎病毒對於SNPs 及肝細胞癌之間的關係的影響（n=1133）。結果：本研究沒有發現兩個SNP 與肝細胞癌或肝硬化之間有任何相關；但在SNP rs4444903 與B 型肝炎病毒量之間發現有負相關，無論是單點資料或是長期追蹤資料都達到顯著，多變項調整之勝算比分別為：單點資料AG vs AA= 0.56 （95%信賴區間：0.35-0.91）；GG vs AA= 0.54（信賴區間：0.33-0.86），長期追蹤資料：AG vs AA= 0.68（95%信賴區間：0.56-0.83）; GG vs AA= 0.67（95%信賴區間：0.56-0.82）。
結論：本研究的結果無法證實SNP rs4444903 對上皮細胞癌的發生的影響，但就結果顯現該SNP 可能在B 型肝炎帶原者身上對病毒的複製活性有影響。此部份需要更詳盡的研究，對於未來B 型肝炎帶原者病情的監控以及接受相關的治療應該會有很大的幫助。 | zh_TW |
| dc.description.abstract | Background: The epidermal growth factor (EGF) signaling pathway affects cell proliferation and differentiation. Polymorphism in the EGF gene may play a role in the
development of epithelial cancers, such as hepatocellular carcinoma (HCC). Methods: We genotyped two EGF functional polymorphisms (rs4444903 at 5’ untranslated region [UTR] and rs11569017 at exon 15) in a cohort of 4432 cancer-free HBsAg-positive men (of whom 200 developed HCC and 4232 remained unaffected through 16 years of follow-up) who were recruited from Government Employee Central Clinics and Chang Gung Memorial Hospital between 1989 and 1992. To evaluate the impact of HBV viral factors on the association between the EGF SNPs and HCC, a longitudinal viral-load study (n=1133) with available data on HBeAg status and HBV genotype and DNA were also conducted within the cohort study. Results: We did not observe any association with the two EGF SNPs for HCC or cirrhosis. However, a statistically, significantly inverse association was found between SNP rs4444903 and circulating HBV DNA level, irrespective of cross-sectional (adjusted odds ratio [95% confidence interval]: AG vs AA= 0.56 [95% CI=0.35-0.91]; GG vs AA= 0.54 [95% CI=0.33-0.86]) or longitudinal (adjusted odds ratio [95% confidence interval]: AG vs AA= 0.68 [95% CI=0.56-0.83]; GG vs AA= 0.67 [95% CI=0.56-0.82]) measure of viral load. Conclusion: Our results argue against a role of the EGF 5’ UTR SNP in epithelial cancers. EGF genetic polymorphism may alter viral replication activity during the development of HCC among HBsAg carriers. A better understanding of the relationship between the EGF 5’ UTR SNP and viral load might be valuable for monitoring HBsAg carriers with HCC under treatment with inhibitors of EGF signaling pathway. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-15T01:27:30Z (GMT). No. of bitstreams: 1 ntu-98-R96842008-1.pdf: 317321 bytes, checksum: a075aa03829da03c9670fbe3194d54ad (MD5) Previous issue date: 2009 | en |
| dc.description.tableofcontents | 1. 中文摘要-----------------------------------------------2
2. Abstract-----------------------------------------------3 3. Introduction-------------------------------------------4 4. Materials and Methods----------------------------------8 5. Results-----------------------------------------------11 6. Discussion--------------------------------------------14 7. References--------------------------------------------18 8. Appendix----------------------------------------------24 | |
| dc.language.iso | en | |
| dc.subject | 世代研究 | zh_TW |
| dc.subject | 表皮生長因子 | zh_TW |
| dc.subject | 基因多型性 | zh_TW |
| dc.subject | 肝細胞癌 | zh_TW |
| dc.subject | B 型肝炎病毒 | zh_TW |
| dc.subject | Gene polymorphism | en |
| dc.subject | Cohort study | en |
| dc.subject | Hepatocellular carcinoma | en |
| dc.subject | Hepatitis B virus | en |
| dc.subject | Epidermal growth factor | en |
| dc.title | 表皮生長因子基因多型性和B型肝炎帶原者之肝細胞癌危險性：世代研究 | zh_TW |
| dc.title | Role of EGF Gene Functional Polymorphism in the Development
of Hepatocellular Carcinoma among Hepatitis B Carriers | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 97-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 張久瑗,郭育良,莊雅惠 | |
| dc.subject.keyword | 表皮生長因子,基因多型性,肝細胞癌,B 型肝炎病毒,世代研究, | zh_TW |
| dc.subject.keyword | Epidermal growth factor,Gene polymorphism,Hepatitis B virus,Hepatocellular carcinoma,Cohort study, | en |
| dc.relation.page | 32 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2009-07-23 | |
| dc.contributor.author-college | 公共衛生學院 | zh_TW |
| dc.contributor.author-dept | 流行病學研究所 | zh_TW |
| 顯示於系所單位： | 流行病學與預防醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-98-1.pdf 未授權公開取用 | 309.88 kB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。